Embodiments of the present invention relate generally to treatment of tissue by application of energy thereto, and particularly to ablation of cardiac or other tissue by application of ultrasound energy.
Atrial fibrillation is a common cardiac arrhythmia involving the atria of the heart. During atrial fibrillation, the atria beat irregularly and out of coordination with the ventricles of the heart. Atrial fibrillation disrupts efficient beating of the heart and may result in blood clotting in the atrium leading to serious medical conditions such as strokes.
Atrial fibrillation is generally caused by abnormal electrical activity in the heart. During atrial fibrillation, electrical discharges may be generated by parts of the atria which do not normally generate electrical discharges, such as pulmonary vein ostia in the atrium. Pulmonary vein isolation is a common medical procedure for treatment of atrial fibrillation.
Ablation technologies currently include unipolar and bipolar techniques. The unipolar techniques employ various energy sources, including radiofrequency (RF), microwave, high intensity focused ultrasound (HIFU), laser, and cryogenic energy sources. The bipolar techniques employ RF energy.
In some embodiments of the present invention, methods and apparatus are provided for application of ultrasound energy to tissue within a body of a subject. For some applications, the ultrasound energy is applied to treat cardiac arrhythmias, such as atrial fibrillation, ventricular fibrillation, and/or ventricular tachycardia. During a minimally invasive procedure, an ultrasound tool is advanced into an organ of the body, such as a heart chamber. The ultrasound tool comprises at least one ultrasound transducer that is configured to transmit treatment energy, e.g., high intensity focused ultrasound (HIFU), towards myocardial tissue, and in particular towards sites within myocardial tissue which are involved in triggering, maintaining, or propagating cardiac arrhythmias, e.g., in the case of atrial fibrillation, pulmonary vein ostia. The treatment energy applied to the myocardial tissue causes ablation of the tissue. As a result of the ablation, scars typically form in the ablated areas. The scars generally block abnormal electrical pulses generated in the pulmonary vein ostia from propagating into the heart chambers, thereby electrically isolating the pulmonary veins from the atrium and preventing cardiac arrhythmias.
For some applications, prior to application of the treatment energy, a reflection-facilitation element is placed at an extramyocardial site, in a vicinity of the myocardial tissue designated for treatment. The reflection-facilitation element provides a reflective region in the extramyocardial site. Typically, the extramyocardial site is within a “pericardial region,” which, as used in the present application, including the claims, consists of one or more regions selected from the group consisting of a region between the pericardium and the myocardium, a region between the visceral pericardium (also known as the epicardium) and the parietal pericardium, and a region outside the pericardium and in contact therewith.
The treatment energy applied by the ultrasound transducer to the sites in the myocardial tissue is reflected from the extramyocardial reflective region back through the myocardial tissue. The treatment energy is thus directed at the myocardial site from two opposing directions, nearly doubling the applied energy, thereby resulting in enhanced ablation of the myocardial tissue. This technique enables the rapid formation of an effective transmural lesion having an increased depth within the myocardium (as viewed from within the heart) and/or increased homogeneity along the depth, compared to that which would be achieved in the absence of the reflection of the ultrasound energy.
For some applications, the reflection-facilitation element comprises a gas-delivery element, which provides the reflective region by delivering a gas to the extramyocardial site. The gas-delivery element, e.g., a needle, is typically inserted through the pericardium and is configured to deliver gas to create a gas-filled pocket within the pericardial region, as defined hereinabove. The gas has a lower density than that of the surrounding tissue within the body, thereby creating a change in acoustic impedance. Due to the change in acoustic impedance, ultrasound waves which reach the gas are reflected. Thus, the gas in the gas-inflated extramyocardial site serves as a reflector for the ultrasound energy. Typically, following inflation of the pericardium with gas, ultrasound energy is applied by the ultrasound transducer in the heart to the designated treatment site in the myocardial tissue that is adjacent to the gas-filled pericardium. The emitted energy reaches the designated treatment site and is reflected by the gas, such that the reflected ultrasound energy passes again through the treatment site.
There is therefore provided in accordance with some applications of the present invention, apparatus including an ultrasound ablation system, which includes:
For some applications, the tissue includes myocardial tissue and the far side of the tissue includes an extramyocardial site, and:
For some applications, the chamber is a left atrium, and the ultrasound transducer is configured to be positioned within the left atrium.
For some applications, the chamber is a chamber selected from the group consisting of the: right atrium, right ventricle, and left ventricle, and the ultrasound transducer is configured to be positioned within the chamber selected from the group.
For some applications, the tissue includes tissue of a subject selected from the group consisting of: nervous tissue, uterine tissue, prostate tissue, lung tissue, and tissue of the gastrointestinal tract and the ultrasound transducer is configured to ablate tissue selected from the group.
For some applications, the ultrasound transducer is configured to apply the ultrasound energy as high intensity focused ultrasound (HIFU) energy.
For some applications, the ultrasound tool further includes an anchoring element, which is configured to temporarily stabilize the tool in the chamber.
For some applications, the anchoring element includes at least one inflatable element, configured to be inflated such that the inflatable element temporarily stabilizes the tool by contacting an inner wall of a blood vessel.
For some applications, the reflection-facilitation element includes a gas-delivery element, configured to provide the reflective region by delivering a gas to the extramyocardial site.
For some applications, the extramyocardial site of the subject is within a pericardial region of the subject that consists of one or more regions selected from the group consisting of: a region between the pericardium and the myocardium, a region between the visceral pericardium and the parietal pericardium, and a region outside the pericardium and in contact therewith, and the reflection-facilitation element is configured to provide the reflective region within the pericardial region.
For some applications, the reflection-facilitation element includes an inflatable element.
For some applications, the reflection-facilitation element includes an acoustic reflector, configured to be delivered to the extramyocardial site of the subject.
For some applications, the reflection-facilitation element is configured to be transthoracically delivered to the extramyocardial site of the subject.
For some applications, the ultrasound tool further includes an arm having a distal end, and the at least one ultrasound transducer is coupled to the distal end of the arm.
For some applications, the ultrasound transducer includes an anticoagulation coating.
For some applications, the reflection-facilitation element includes a mechanical surgical retractor.
For some applications, the ultrasound transducer includes an array of ultrasonic elements.
For some applications, the system further includes a control unit, which is configured to monitor an ultrasonic parameter of the tissue.
For some applications, the control unit is configured to perform an analysis of the parameter, and, responsively to the analysis, to drive the ultrasound transducer to cease ablating the tissue.
For some applications, the ultrasonic parameter is a time of flight of the ultrasound energy applied by the ultrasound transducer and reflected by the reflective region.
For some applications, the control unit is configured to ascertain a temperature of the tissue responsively to the time of flight.
For some applications, the control unit is configured to use signal processing to eliminate sinusoidal behavior exhibited by the time of flight due to atrial contractions.
For some applications, the control unit is configured to use an average moving window to eliminate the sinusoidal behavior.
For some applications, the ultrasonic parameter is selected from the group consisting of: an amplitude of the ultrasound energy applied by the ultrasound transducer and reflected by the reflective region, a scatter intensity of the reflected ultrasound energy, sub-harmonics of the reflected ultrasound energy, second and higher harmonic reflections of the reflected ultrasound energy, an attenuation of the reflected ultrasound energy, and a non-linear parameter of the reflected ultrasound energy.
For some applications, an additional tool is configured to ablate the tissue subsequently to the ultrasound transducer applying ultrasound energy to the tissue.
For some applications, the additional tool includes a tool selected from the group consisting of: a radiofrequency (RF) tool, an ultrasound tool, and a cryoablation tool.
There is further provided in accordance with some applications of the present invention, apparatus including an ultrasound ablation system, which includes:
For some applications, the chamber is a left atrium, and the reflection-facilitation element is configured to be placed within the left atrium, and to provide the intracardiac reflective region within the left atrium.
For some applications, the chamber is a chamber selected from the group consisting of the: right atrium, right ventricle, and left ventricle and the reflection-facilitation element is configured to be positioned within the chamber selected from the group.
For some applications, the ultrasound transducer is configured to apply the ultrasound energy as high intensity focused ultrasound (HIFU) energy.
For some applications, the extramyocardial site of the subject is within a pericardial region of the subject that consists of one or more regions selected from the group consisting of: a region between the pericardium and the myocardium, a region between the visceral pericardium and the parietal pericardium, and a region outside the pericardium and in contact therewith, and the ultrasound transducer is configured to be positioned within the pericardial region.
There is yet further provided in accordance with some applications of the present invention, a method including:
For some applications, providing the reflective region includes using a reflective-facilitation element to provide the reflective region.
For some applications, the chamber is a left atrium, and advancing includes advancing the ultrasound tool into the left atrium.
For some applications, activating includes activating the ultrasound transducer to apply the ultrasound energy as high intensity focused ultrasound (HIFU) energy.
For some applications, the method includes applying radiofrequency (RF) energy to the myocardial tissue following activating the ultrasound transducer to ablate myocardial tissue.
For some applications, advancing the ultrasound tool includes temporarily stabilizing the ultrasound tool in the chamber using an anchoring element.
For some applications, providing the reflective region includes delivering a gas to the extramyocardial site.
For some applications, the extramyocardial site is within a pericardial region of the subject that consists of one or more regions selected from the group consisting of: a region between the pericardium and the myocardium, a region between the visceral pericardium and the parietal pericardium, and a region outside the pericardium and in contact therewith, and providing the reflective region includes providing the reflective region within the pericardial region.
For some applications, providing the reflective region includes inflating an inflatable element at the extramyocardial site with a fluid selected from the group consisting of: a gas, and a mixture of a liquid and a gas.
For some applications, providing the reflective region includes delivering an acoustic reflector to the extramyocardial site.
For some applications, providing the reflective region includes inserting a mechanical surgical retractor into the extramyocardial site.
For some applications, the ultrasound transducer includes an array of ultrasonic elements, and activating the ultrasound transducer includes activating the array of ultrasonic elements.
For some applications, activating further includes monitoring an ultrasonic parameter of the myocardial tissue.
For some applications, activating further includes performing an analysis of the parameter, and, responsively to the analysis, ceasing ablating the myocardial tissue.
For some applications, the parameter is a time of flight of the ultrasound energy applied by the ultrasound transducer and reflected by the reflective region.
For some applications, monitoring includes ascertaining a temperature of the tissue responsively to the time of flight.
For some applications, monitoring includes using signal processing to eliminate sinusoidal behavior exhibited by the time of flight due to atrial contractions.
For some applications, using the signal processing includes using an average moving window to eliminate the sinusoidal behavior.
For some applications, the ultrasonic parameter is selected from the group consisting of an amplitude of the ultrasound energy applied by the ultrasound transducer and reflected by the reflective region, a scatter intensity of the reflected ultrasound energy, sub-harmonics of the reflected ultrasound energy, second and higher harmonic reflections of the reflected ultrasound energy, an attenuation of the reflected ultrasound energy, and a non-linear parameter of the reflected ultrasound energy.
There is still further provided in accordance with some applications of the present invention, a method including:
For some applications, providing the reflective region includes using a reflective-facilitation element to provide the reflective region.
For some applications, providing the reflective region includes inserting an inflatable element into the chamber, and inflating the inflatable element with a fluid selected from the group consisting of a gas, and a mixture of a liquid and a gas.
For some applications, the chamber is a left atrium, and providing includes providing the reflective region within the left atrium.
For some applications, activating includes activating the ultrasound transducer to apply the ultrasound energy as high intensity focused ultrasound (HIFU) energy.
For some applications, the extramyocardial site of the subject is within a pericardial region of the subject that consists of one or more regions selected from the group consisting of: a region between the pericardium and the myocardium, a region between the visceral pericardium and the parietal pericardium, and a region outside the pericardium and in contact therewith, and positioning includes positioning the at least one ultrasound transducer within the pericardial region.
There is additionally provided in accordance with some applications of the present invention, a method including:
For some applications, the tissue includes myocardial tissue and the far side of the tissue includes an extramyocardial site, and:
For some applications, the tissue includes tissue of a subject selected from the group consisting of: nervous tissue, uterine tissue, prostate tissue, lung tissue, and tissue of the gastrointestinal tract, and ablating the tissue includes ablating the selected tissue.
For some applications, providing the reflective region includes placing a reflective-facilitation element at the far side of the tissue, and using the reflective-facilitation element to provide the reflective region.
For some applications, providing the reflective region includes providing a gas at the far side.
There is still additionally provided in accordance with some applications of the present invention, a method including:
For some applications, assessing includes:
For some applications, monitoring the ultrasound parameter includes monitoring an amplitude of the ultrasound energy reflected by the reflective region.
For some applications, the ultrasound parameter is selected from the group consisting of: a scatter intensity of the reflected ultrasound energy, sub-harmonics of the reflected ultrasound energy, second and higher harmonic reflections of the reflected ultrasound energy, an attenuation of the reflected ultrasound energy, and a non-linear parameter of the reflected ultrasound energy, and monitoring the ultrasound parameter includes monitoring the selected ultrasound parameter.
For some applications, assessing includes receiving sound generated by the providing of the reflective region.
For some applications, assessing includes determining whether the reflective region is within a pericardium of the subject.
For some applications, providing the reflective region includes transthoracically advancing a reflection-facilitation element toward the desired location.
For some applications, providing the reflective region includes transvenously advancing a reflection-facilitation element toward the desired location.
For some applications, the desired location is within a pericardial region of the subject that consists of one or more regions selected from the group consisting of: a region between the pericardium and the myocardium, a region between a visceral pericardium and a parietal pericardium, and a region outside the pericardium and in contact therewith, and providing the reflective region includes providing the reflective region within the pericardial region.
There is yet additionally provided in accordance with some applications of the present invention, a method including:
There is further additionally provided in accordance with some applications of the present invention, a method for monitoring ablation of a tissue site, the method including:
For some applications, the method includes the step of performing an analysis of the ultrasound parameter, and, responsively to the analysis, determining a level of ablation of the tissue site.
For some applications, the method includes the step of performing an analysis of the ultrasound parameter, and, responsively to the analysis, determining a continuity of an ablation lesion throughout the tissue site.
For some applications, monitoring the ultrasound parameter includes monitoring an amplitude of the ultrasound energy reflected by the reflective region.
For some applications, the ultrasound parameter is selected from the group consisting of: a scatter intensity of the reflected ultrasound energy, sub-harmonics of the reflected ultrasound energy, second and higher harmonic reflections of the reflected ultrasound energy, an attenuation of the reflected ultrasound energy, and a non-linear parameter of the reflected ultrasound energy, and monitoring the ultrasound parameter includes monitoring the selected ultrasound parameter.
There is still additionally provided in accordance with some applications of the present invention, apparatus including an ultrasound monitoring system, which includes:
There is yet additionally provided in accordance with some applications of the present invention, apparatus for monitoring ablation of a tissue site, the apparatus including:
For some applications, the tissue site includes a heart chamber of the subject, and the ultrasound transducer is configured to be positioned within the heart chamber.
For some applications, the chamber is a left atrium, and the ultrasound transducer is configured to be positioned within the left atrium.
For some applications, the chamber is a chamber selected from the group consisting of the: right atrium, right ventricle, and left ventricle, and the ultrasound transducer is configured to be positioned within the chamber selected from the group.
For some applications, the tissue site includes tissue of a subject selected from the group consisting of: nervous tissue, uterine tissue, prostate tissue, lung tissue, and tissue of the gastrointestinal tract and the ultrasound transducer is configured to be positioned at a tissue site selected from the group.
For some applications, the processor is further configured to perform an analysis of the ultrasound parameter, and, responsively to the analysis, to determine a level of ablation of the tissue site.
For some applications, the processor is further configured to perform an analysis of the ultrasound parameter, and, responsively to the analysis, to determine a continuity of an ablation lesion throughout the tissue site.
For some applications, the processor is further configured to perform an analysis of a plurality of ultrasound parameters, and, responsively to the analysis, to determine a continuity of an ablation lesion throughout the tissue site.
For some applications, the ultrasound parameter includes an amplitude of the ultrasound energy reflected by the reflective region, and the processor is configured to monitor the amplitude of the ultrasound energy reflected by the reflective region.
For some applications, the ultrasound parameter is selected from the group consisting of: a scatter intensity of the reflected ultrasound energy, sub-harmonics of the reflected ultrasound energy, second and higher harmonic reflections of the reflected ultrasound energy, an attenuation of the reflected ultrasound energy, and a non-linear parameter of the reflected ultrasound energy, and the processor is configured to monitor the selected ultrasound parameter.
There is still further provided in accordance with some applications of the present invention, apparatus including an ablation system, which includes:
For some applications, the ablation tool includes a radiofrequency (RF) ablation tool configured to ablate the tissue by applying RF energy to the near side of the tissue.
For some applications, the ablation tool includes a cryoablation tool.
There is additionally further provided accordance with some applications of the present invention, a method including:
For some applications, the ablation tool includes a radiofrequency (RF) ablation tool and activating the ablation tool includes activating the radiofrequency (RF) ablation tool to apply energy to the near side of the tissue.
For some applications, the ablation tool includes a cryoablation tool and activating the ablation tool includes activating the cryoablation tool.
The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawings, in which:
Reference is made to
For some applications, distal portion 32 comprises an arm 30 that is coupled to hinge 44. Arm 30 typically comprises, at a distal end thereof, the at least one ultrasound transducer 40. Tool 20 may comprise a plurality of arms 30 and any number of ultrasound transducers 40. For some applications, ultrasound transducer 40 is coupled to an element of tool 20 other than the arm.
For some applications, ultrasound tool 20 further comprises an anchoring element 48, which is configured to temporarily stabilize the tool during application of the treatment energy. For example, the anchoring element may temporarily anchor the distal end of tool 20 in a pulmonary vein. For some applications, as shown in the figures, anchoring element 48 comprises an inflatable element 50, e.g., comprising a balloon, which may be coupled to the distal end of distal portion 32 of shaft 23. Optionally the inflatable element is shaped so as to provide a passage therethrough for blood flow, such as described hereinbelow with reference to
Tool 20 is shown in
Reference is now made to
Typically, ultrasound transducer 40 is configured to emit high intensity focused ultrasound (HIFU) waves towards a target tissue. For some applications, a surface of transducer 40 is coated with an anticoagulation coating, in order to reduce coagulation of blood on the transducer as a result of heating of the transducer. For example, the anticoagulation coating may comprise a heparin anticoagulant coating such as Carmeda BioActive Surface (CBAS®) as provided by Carmeda AB, a W.L. Gore company. Additionally or alternatively, the transducer is actively cooled (e.g., using a cooled liquid or a thermoelectric element). For some applications, the transducer is passively cooled by being shaped and oriented in a way that facilitates the flow of blood over the transducer. For example, the transducer may be convex or concave, and may face oncoming flow exiting blood vessel 80, such that the flow convectively drives away heat accumulating at the surface of the transducer. Alternatively, if the transducer is flat, then to achieve passive cooling, the transducer is typically positioned near to the orifice of blood vessel 80 at at least 10 degrees, e.g., at least 90 degrees, but such that it does not directly face the oncoming flow.
For some applications, distal portion 32 comprises a telescopically collapsible and extendable element 34, which facilitates the telescopic extension and collapse of distal portion 32.
Inflatable element 50 is shown in
Reference is made to
Tool 20 is located adjacent to an orifice of a blood vessel 80, e.g., a pulmonary vein ostium, and to cardiac tissue, e.g., an atrial wall 100. Hinge 44 typically facilitates deflection of arm 30 such that arm 30 is deflected laterally, as indicated by arrow 12A (e.g., by between 30 and 90 degrees, such as by 45 degrees, as shown) from a position that is aligned with a longitudinal axis of tool 20. The angle of deflection of arm 30 is typically controllable by the physician during a procedure. Deflection of arm 30 brings ultrasound transducer 40 into proximity of (e.g., in contact with or within a few millimeters of) the endocardium of cardiac tissue designated for ablation treatment, such that ultrasound transducer 40 is aimed at the designated site. There is generally no need for firm contact between ultrasound transducer 40 and the endocardium. In some applications, the site designated for treatment is cardiac tissue in the atrial wall surrounding an orifice of a blood vessel, e.g., a pulmonary vein ostium.
For some applications, distal portion 32 of tool 20 is telescopically extended into blood vessel 80 in the direction indicated by an arrow 13A. For some applications, tool 20 comprises inflatable element 50, e.g., a balloon, coupled to the distal end of distal portion 32. For applications in which tool 20 comprises anchoring element 48, during opening of tool 20 into an operative state, and subsequent application of treatment energy, the anchoring element stabilizes the tool against the wall of blood vessel 80 during application of treatment energy and rotation of arm 30 or another element of tool 20 (described hereinbelow). For example, for applications in which anchoring element 48 comprises inflatable element 50, inflatable element 50 is inflated (by filling the inflatable element with fluid, i.e., a gas or a liquid) to apply pressure to a wall of blood vessel 80, in order to stabilize and maintain tool 20 in place. Inflatable element 50 may be inflated prior to deflection of arm 30, so as to stabilize and maintain tool 20 in place during the deflection of arm 30 and subsequent application of treatment energy. For some applications, inflatable element 50 comprises an annular inflatable element that surrounds a distal portion of tool 20.
It is to be noted that an inflation conduit 7 is coupled at a distal end thereof to inflatable element 50, and extends through a lumen of shaft 23 and toward distal portion 32 of tool 20. When the operating physician desires to inflate element 50, fluid (i.e., a gas or liquid) is delivered via the conduit toward inflatable element 50 from a fluid source that is disposed outside the body of the subject. The fluid may be pressurized.
Reference is still made to
Reference is made to
As shown in
As shown in
Typically, following the creation of the first lesion in the ablation site in atrial wall 100, tool 20 is rotated slightly, e.g., by between 1 and 10 degrees (e.g., between 2.5 and 7.5 degrees), such that ultrasound transducer 40 is now aimed at an adjacent location of atrial wall 100, for creation of an additional lesion. This procedure is typically repeated until a 360-degree circumferential lesion surrounding the orifice of blood vessel 80 is formed. For some applications, transducer 40 is rotated slowly while continuously transmitting ultrasound energy, thus creating a continuous circular lesion surrounding the orifice of blood vessel 80. For some applications, the rotation is performed manually by the physician performing the procedure. Alternatively, the rotation is performed by a motor. For some applications, system 10 comprises a control unit that senses when each individual lesion has been formed (e.g., by monitoring temperature, as described hereinbelow with reference to
For some applications, transducer 40 is configured to provide the operating physician with information regarding the path of ablation. For such applications, transducer 40 may be configured to indicate a direction that the transducer is facing such that the path of ablation is indicated on a mapping system viewed by the physician.
Reference is made to
Alternatively, reflection-facilitation element 12 comprises another material that has an acoustic impedance different from that of water, typically substantially different. For example, the element may comprise a sponge, an expanded polystyrene foam (e.g., Styrofoam®, Dow Chemical Company), or another material that contains a large amount of air. Ultrasound energy that is transmitted towards tissue of atrial wall 100 is reflected due to the different acoustic impedance, such that the return energy waves pass again through the tissue.
For some applications, reflection-facilitation element 12 comprises a mechanical surgical retractor, which is configured to separate the pericardium from the heart. The space thus created naturally fills with gas, thereby creating the reflective region. Surgical retractors are widely available from numerous manufacturers.
Reference is made to
The inflatable element is typically inflated with a fluid having a lower density than water, such as a gas (e.g., carbon dioxide) or a mixture of fluid and gas. The low-density fluid functions as the reflective region described hereinabove. Ultrasound energy that is transmitted towards tissue of atrial wall 100 is reflected due to the fluid-filled (e.g., gas-filled) balloon, such that the return energy waves pass again through the tissue. For some applications, inflatable element 122 is coupled to a double-channeled catheter. A first one of the channels is in fluid communication with the interior of the inflatable element, for delivering the fluid (gas or mixture of gas and liquid) to inflate the inflatable element. A second one of the channels is positioned in fluid communication with the pericardial region, typically the region between the pericardium and the myocardium. The second channel is used to deliver a gas to the pericardial region. For some applications, the channels are defined by two tubes, an inner tube positioned within an outer tube. For example, the inner tube may be in fluid communication with the inflatable element, and the outer tube may be in fluid communication with the pericardial region. For example, the outer tube may be shaped so as to define slots therethrough, through which the gas is injected into the pericardial region. For some applications, the inflatable element helps separate the membrane of the myocardium from that of the pericardium, functioning as a retractor.
Reference is made to
Reference is made to
As shown in
For some applications, as mentioned above, distal portion 32 of tool 20 is telescopically extended into the pulmonary vein, such that anchoring element 48 (e.g., inflatable element 50) is disposed within a lumen of pulmonary vein 50. Anchoring element 48 is shown comprising inflatable element 50, which is shown inflated, applying pressure to a wall of the pulmonary vein, in order to stabilize and maintain tool 20 in place during application of treatment energy. Alternatively, anchoring is not provided, or other anchoring techniques are used, such as described herein. An exploded view of ultrasound transducer 40 shows the initiation of treatment by applying ablating ultrasound waves to the tissue of atrial wall 100.
It is to be noted that system 10 can be used to treat other types of cardiac arrhythmia such as ventricular tachycardia. For such applications, tool 20 is advanced into a ventricle of a subject and lesions are created by ablation of tissue in the ventricle by application of ultrasound energy in accordance with applications of the present invention.
Reference is again made to
For some applications, the ultrasound HIFU energy application techniques described herein are practiced in combination with other types of ablation, such as cryoablation and/or radiofrequency (RF) ablation.
It is also to be noted that application of treatment energy to sites within a chamber of the heart is not limited to blood vessel orifices but may be applied to any region in the heart which is involved in triggering or maintaining cardiac arrhythmias.
Reference is still made to
For some applications, a configuration of transducer 40 allows ablating a lesion in tissue of the subject, which is less than 360 degrees, substantially without rotating the transducer. The lesion is typically at least 10 degrees, e.g., at least 90 degrees or at least 180 degrees, and/or the lesion is less than 300 degrees, e.g., less than 270 degrees. For some applications, this less-than-360 degree ablation is performed one or both of the left pulmonary veins, in order to avoid any potential damage to the mitral valve.
Reference is again made to
Additionally or alternatively, some applications of the present invention reduce potential damage to the esophagus that may be caused by ablation procedures performed on the heart. Typically, for applications in which reflection-facilitation element 12 delivers gas to inflate the pericardium, the gas creates a gas-filled barrier between the esophagus and the ablation site, thereby protecting the esophagus from potential damage by the applied ultrasound energy.
For some applications, system 10 is configured to continuously or periodically monitor the treated tissue during treatment, in order to assess whether the ablation is sufficient. For some applications, the system performs the monitoring by electrical mapping of the tissue, such that conductance of electrical signals is mapped and the need for further treatment is assessed. For some applications, a multi-electrode catheter for mapping of conductance following application of treatment is used.
For some applications, system 10 monitors the treated tissue using ultrasound, typically to detect the temperature of the treated tissue. Various ultrasound parameters are dependent on the temperature of the tissue. For example, the speed of sound is dependent on the temperature of the tissue. In the case of a muscle (or atrial wall), the speed of sound increases as the temperature is elevated. Thus the time of flight (TOF) decreases as the temperature is elevated, assuming that the distance that the sound waves travel is fixed. The beating heart is more complicated, since due to atrial contraction the distance changes (even if the transducer is fixed in the same position or distance from the atrial wall). However, the distance change is predictable, and thus, for some applications, is used to extract the temperature change, as described below. For some applications, the ultrasound parameter is selected from the group consisting of: an amplitude of the ultrasound energy applied by the ultrasound transducer and reflected by the reflective region, a scatter intensity of the reflected ultrasound energy, sub-harmonics of the reflected ultrasound energy, second and higher harmonic reflections of the reflected ultrasound energy, an attenuation of the reflected ultrasound energy, and a non-linear parameter of the reflected ultrasound energy.
Additionally or alternatively, system 10 monitors ablation of the tissue using ultrasound. As described hereinabove, for some applications, the ultrasound transducer is rotated slowly while continuously transmitting ablating ultrasound energy, thus creating a continuous circular lesion surrounding the orifice of blood vessel. As provided by some applications of the present invention, following ablation of the tissue, the ultrasound transducer is activated to apply low intensity ultrasound energy to the ablated tissue such that at least a portion of the transmitted energy is reflected by the tissue onto the ultrasound transducer. System 10 typically comprises a processor configured to monitor a pattern of the reflected energy (echo) received by transducer 40. If the circular lesion is continuous, the echo pattern shows a continuous pattern with generally steady intensity. If the circular lesion is not continuous and gaps appear in the ablated tissue, the echo pattern presents varying intensities. For some applications, further energy application to the tissue is applied following monitoring of the treated tissue and assessment of the tissue ablation. For such applications, additional “touch up” treatment may be applied by any suitable ablation-generating method e.g., ultrasound (e.g., HIFU or low intensity focused or non-focused ultrasound) and/or by RF energy, and/or by cryoablation.
The graph in
The graph in
When the monitored temperature shows that the target temperature has been obtained, the ultrasound transmission is ceased, and the transducer is rotated to a different radial location, either manually by the physician, or by a motor, e.g., driven by a control unit of system 10.
For some applications, system 10 alternatively or additionally measures other ultrasound parameters, such as the amplitude of reflected ultrasound waves, scatter intensity, sub-harmonics, second and higher harmonic reflections, attenuation and/or non-linear parameters, The system uses these measured parameters as indicative of change in the treated tissue. When sufficient change is obtained, the ultrasound transmission is ceased and the transducer rotated, either manually by the physician, or by a motor, e.g., driven by a control unit of system 10.
It is noted that inflatable element 50, the telescopic expansion of distal portion 32 of tool 20, arm 30, and the 360 rotation of tool 20 are described hereinabove by way of illustration and not limitation, and the scope of the present invention includes a system that includes only some, or none, of these elements.
Reference is now made to
For some applications as described hereinabove, the ultrasound energy is applied to treat cardiac arrhythmias, such as ventricular fibrillation; and/or ventricular tachycardia. For such applications, the ultrasound energy is directed towards myocardial tissue sites (e.g., the interventricular septum) which are involved in triggering, maintaining, or propagating these ventricular cardiac arrhythmias.
For example, for some applications (not shown) in order to create a lesion in the interventricular septum, a reflection-facilitation element comprising an inflatable element (e.g., a balloon) is inserted into a ventricle of the subject. The inflatable element is typically inflated with a fluid having a lower density than water, such as a gas (e.g., carbon dioxide). It is noted that in this context in the specification and in the claims, the term “fluid” includes gases and liquids. The low-density fluid functions as the reflective region described hereinabove. An ultrasound transducer is typically placed in the opposite ventricle, and ultrasound energy that is transmitted by the transducer towards tissue of the interventricular septum is reflected due to the fluid-filled (e.g., gas-filled) balloon, such that the return energy waves pass again through the tissue. Similarly, inserting the fluid-filled (e.g., gas-filled) balloon into a ventricle may be used to reflect the ultrasound energy on to any region of tissue of the opposite ventricle, for creating a lesion in the tissue in accordance with some applications of the present invention.
Reference is now made to
Reference is made to
Reference is first made to
Reference is now made to
Reference is made to
Reference is again made
It is noted that for some applications the use of a gas-filled region as described herein is used in combination with other ablation techniques for example, cryoablation and/or radiofrequency (RF) ablation. Typically, the use of the gas-filled region improves efficacy of the ablation treatment as well as enhancing safety. The gas-filled region typically isolates the treated area such that cryoablation treatment is improved. Additionally or alternatively, the gas-filled region typically improves electrical conductivity improving the effects of RF treatment.
Although techniques of the present invention have generally been described herein as being applied to cardiac tissue, these techniques may additionally be used, mutatis mutandis, to treat other tissue of a subject, such as liver tumors or varicose veins or nervous tissue. For some applications, these techniques may additionally be used, mutatis mutandis, to treat other tissue of the subject e.g., a uterus and or one or more locations along the gastrointestinal tract. For some applications these techniques may additionally be used, mutatis mutandis, to treat prostate tissue of the subject, e.g., by inserting the ultrasound transducer through the urethra and providing a reflective region in the rectum, e.g., by inflating the rectum or positioning a gas-filled balloon in the rectum. For some applications, these techniques may additionally be used, mutatis mutandis, to treat the lungs and lung vasculature. For such applications, a gas present in lung of the subject typically provides a reflective region for enhancing application of treatment energy to adjacent tissue.
The techniques described herein are used to provide a reflective region at a far side of the tissue, by placing a reflective-facilitation element at the far side, and to ablate the tissue by applying ultrasound energy to a near side of the tissue such that at least a portion of the applied energy is reflected onto the tissue by the reflective region. Additionally or alternatively, these techniques may be used to monitor a tissue of a subject by providing a reflective region at a far side of the tissue, by placing a reflective-facilitation element at the far side and applying non-ablating ultrasound energy to a near side of the tissue, such that at least a portion of the applied energy is reflected onto the tissue by the reflective region. It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
The present application is the U.S. national phase of PCT Application no. PCT/IL2011/000382 to Tsoref et al., filed May 12, 2011, which claims the priority of and is a continuation-in-part of: U.S. Ser. No. 12/780,240 to Tsoref et al., entitled “Reflectance-facilitated ultrasound treatment,” filed on May 14, 2010, published as US2011-0282249, and issued as U.S. Pat. No. 8,617,150 to Tsoref et al., which is incorporated herein by reference; and U.S. Ser. No. 13/015,951 to Tsoref et al., entitled “Reflectance-facilitated ultrasound treatment and monitoring” filed on Jan. 28, 2011, published as US 2011-0282203, and issued as U.S. Pat. No. 8,956,346 to Tsoref et al., which is incorporated herein by reference.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/IL2011/000382 | 5/12/2011 | WO | 00 | 1/9/2013 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2011/141918 | 11/17/2011 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4619247 | Inoue et al. | Oct 1986 | A |
5676692 | Sanghvi et al. | Oct 1997 | A |
5735280 | Sherman et al. | Apr 1998 | A |
5776063 | Dittrich et al. | Jul 1998 | A |
5817022 | Vesely | Oct 1998 | A |
5827216 | Igo et al. | Oct 1998 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6050943 | Slayton et al. | Apr 2000 | A |
6064902 | Haissaguerre et al. | May 2000 | A |
6083166 | Holdaway et al. | Jul 2000 | A |
6128523 | Bechtold et al. | Oct 2000 | A |
6216704 | Ingle et al. | Apr 2001 | B1 |
6241727 | Tu et al. | Jun 2001 | B1 |
6425877 | Edwards | Jul 2002 | B1 |
6575969 | Rittman et al. | Jun 2003 | B1 |
6605084 | Acker et al. | Aug 2003 | B2 |
6635054 | Fjield et al. | Oct 2003 | B2 |
6641579 | Bernardi et al. | Nov 2003 | B1 |
6659950 | Taheri | Dec 2003 | B2 |
6672312 | Acker | Jan 2004 | B2 |
6685639 | Wang et al. | Feb 2004 | B1 |
6701931 | Sliwa, Jr. et al. | Mar 2004 | B2 |
6805129 | Pless et al. | Oct 2004 | B1 |
7022105 | Edwards | Apr 2006 | B1 |
7037306 | Podany et al. | May 2006 | B2 |
7226440 | Gelfand et al. | Jun 2007 | B2 |
7311701 | Gifford et al. | Dec 2007 | B2 |
7326201 | Fjield et al. | Feb 2008 | B2 |
7565191 | Burbank et al. | Jul 2009 | B2 |
7662099 | Podany et al. | Feb 2010 | B2 |
8197409 | Foley et al. | Jun 2012 | B2 |
20010003798 | McGovern et al. | Jun 2001 | A1 |
20020091427 | Rappaport et al. | Jul 2002 | A1 |
20030018256 | Sasaki et al. | Jan 2003 | A1 |
20040034339 | Stoller et al. | Feb 2004 | A1 |
20040097788 | Mourlas et al. | May 2004 | A1 |
20040162507 | Govari | Aug 2004 | A1 |
20040162550 | Govari et al. | Aug 2004 | A1 |
20050020921 | Glassell et al. | Jan 2005 | A1 |
20050080469 | Larson et al. | Apr 2005 | A1 |
20050165298 | Larson et al. | Jul 2005 | A1 |
20050203410 | Jenkins | Sep 2005 | A1 |
20050251125 | Pless et al. | Nov 2005 | A1 |
20060009753 | Fjield et al. | Jan 2006 | A1 |
20060058711 | Harhen et al. | Mar 2006 | A1 |
20060079868 | Makin et al. | Apr 2006 | A1 |
20060100514 | Lopath | May 2006 | A1 |
20060184048 | Saadat | Aug 2006 | A1 |
20060241523 | Sinelnikov et al. | Oct 2006 | A1 |
20070004984 | Crum et al. | Jan 2007 | A1 |
20070093420 | Yeomans et al. | Apr 2007 | A1 |
20070239077 | Azhari et al. | Oct 2007 | A1 |
20070265610 | Thapliyal et al. | Nov 2007 | A1 |
20080015445 | Saadat et al. | Jan 2008 | A1 |
20080033415 | Rieker et al. | Feb 2008 | A1 |
20080058682 | Azhari et al. | Mar 2008 | A1 |
20080091109 | Abraham | Apr 2008 | A1 |
20090048514 | Azhari et al. | Feb 2009 | A1 |
20090062790 | Malchano et al. | Mar 2009 | A1 |
20090137900 | Bonner et al. | May 2009 | A1 |
20090192506 | Vaska et al. | Jul 2009 | A9 |
20090247912 | Warnking | Oct 2009 | A1 |
20090326511 | Shivkumar | Dec 2009 | A1 |
20100036292 | Darlington et al. | Feb 2010 | A1 |
20100130836 | Malchano et al. | May 2010 | A1 |
20100168624 | Sliwa | Jul 2010 | A1 |
20110178541 | Azhari | Jul 2011 | A1 |
20110184322 | Brawer et al. | Jul 2011 | A1 |
20110251524 | Azhari et al. | Oct 2011 | A1 |
20110282203 | Tsoref et al. | Nov 2011 | A1 |
20110282249 | Tsoref et al. | Nov 2011 | A1 |
20120130363 | Kim et al. | May 2012 | A1 |
20120296240 | Azhari et al. | Nov 2012 | A1 |
Number | Date | Country |
---|---|---|
9940957 | Aug 1999 | WO |
03097162 | Nov 2003 | WO |
2006072928 | Jul 2006 | WO |
2007134258 | Nov 2007 | WO |
2011141918 | Nov 2011 | WO |
2012120495 | Sep 2012 | WO |
Entry |
---|
International Search Report and Written Opinion dated Aug. 12, 2013 PCT/IL13/50134. |
Non-Final Office Action, dated May 8, 2014, for U.S. Appl. No. 13/015,951. |
USPTO NFOA dated May 17, 2013 in connection with U.S. Appl. No. 12/780,240. |
Eric Buch, MD, et al; “Intra-Pericardial Balloon Retraction of the Left Atrium: A Novel Method to Prevent Esophageal Injury During Catheter Ablation”, Heart Rhythm, Oct. 2008; vol. 5, Issue 10, pp. 1473-1475. |
David Cassak, et al; “Endosense: Facing Technology and Financing Challenges in AF”, In-Vivo: The Business & Medicine Report, Mar. 2010, pp. 36-44. |
William E. Cohn, MD, et al; “Contrast Pericardiography Facilitates Intrapericardial Navigation Under Fluoroscopy”, An. Thorac Surg; vol. 90, pp. 1537-1540 Accepted for publication Jun. 7, 2010. |
Luigi Di Biase, MD, et al; “Prevention of phrenic nerve injury during epicardial ablation: Comparison of methods for separating the phrenic nerve from the epicardial surface”, Heart Rhythm; Epub Mar. 19, 2009; vol. 6, Issue 7, pp. 957-961. |
Srijoy Muhapatra, MD, et al; “Pressure frequency characteristics of the pericardial space and thorax during subxiphoid access for epicardial ventricular tachycardia ablation”, Heart Rhythm; Epub Jan. 15, 2010; vol. 7, Issue 5, pp. 604-609. |
Seiichiro Matsuo, MD et al; “Novel Technique to Prevent Left Phrenic Nerve Injury During Epicardial Catheter Ablation”, Circulation, Jun. 3, 2008, vol. 117, Issue 22, 2 pages. |
Shiro Nakahara, MD, et al; “Intrapericardial balloon placement for prevention of collateral injury during catheter ablation of the left atrium in a porcine model”, Heart Rhythm, Epub Sep. 17, 2009; vol. 7, Issue 1, pp. 81-87. |
Frederic Sacher, MD et al; “Phrenic Nerve Injury After Catheter Ablation of Atrial Fibrillation”, Indian Pacing Electrophysiology Journal, vol. 7, Issue 1, pp. 1-6; Published online Jan. 1, 2007. |
Richard B. Schuessler, PhD et al; “Animal studies of epicardial atrial ablation”, Heart Rhythm, Dec. 2009; vol. 6, 12 Suppl. pp. S41-S45. |
Jeanne Shen, BS et al; “The surgical treatment of atrial fibrillation”, Heart Rhythm, vol. 6, No. 8S, August Supplement 2009, 7 pages. |
S. Tanaka et al; “Development of a New Vascular Endoscopic System for Observing Inner Wall of Aorta Using Intermittent Saline Jet”, World Congress on Medical Physics and Biomedical Engineering, Sep. 7-12, 2009, Munich, Germany, 8 pages. |
Guillermo J. Tearney, MD, PhD et al; “Three-Dimensional Coronary Artery Microscopy by Intracoronary Optical Frequency Domain Imaging”, JAAC Cardiovasc Imaging, Nov. 2008; vol. 1, Issue 6, pp. 752-761. |
International Search Report dated Jul. 31, 2008; PCT/US07/68818. |
International Search Report and Written Opinion dated Oct. 26, 2011 PCT/IL11/00382. |
International Preliminary Report on Patentability dated Nov. 20, 2012; PCT/IL2011/000382. |
International Search Report and Written Opinion dated Sep. 17, 2012; PCT/IL2012/000100. |
USPTO NFOA mailed Dec. 20, 2012 in connection with U.S. Appl. No. 11/653,115. |
USPTO NFOA dated Feb. 19, 2013 in connection with U.S. Appl. No. 13/010,555. |
USPTO RR dated Feb. 25, 2013 in connection with U.S. Appl. No. 12/780,240. |
Number | Date | Country | |
---|---|---|---|
20130103028 A1 | Apr 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12780240 | May 2010 | US |
Child | 13697831 | US | |
Parent | 13015951 | Jan 2011 | US |
Child | 12780240 | US |